Cabaletta Bio, Inc. (CABA) saw a decrease of 7.01% in the aftermarket because the company announced the Presentation of Preclinical Data Supporting PLA2R-CAART. However, the last trading session concluded at $12.26 with an incline of 0.08%.
CABA Announces Presentation of Preclinical Data Supporting PLA2R-CAART
On 15th October 2021, CABA announced that ASN Kidney Week 2021 will be used to provide results from in vitro investigations. This will support the background of the study validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell candidates. Moreover, the committee will present findings as an oral abstract at the American Society of Nephrology’s (ASN) Kidney Week 2021 on Friday, Nov 5, 4:30 PM – 6:00 PM PDT.
Individuals with PLA2R membranous nephropathy are now treated with broad immune suppression. This includes B cell depletion with rituximab, which typically takes many treatments and can induce severe infections in some patients. CABA hopes to build a highly precise therapy that delivers safety, effectiveness, and longevity for people who suffer from this inflammatory illness. This is based on the platform for CAART therapeutic compounds that are farther along in investigation, such as DSG3-CAART and MuSK-CAART.
New Appointment in CABA
CABA stated on 7th September 2021 that Michael Gerard is the new general counsel of the company. Mr. Gerard had previously worked at Spark Therapeutics, a Roche Group company. He helped worldwide gene therapy Manufacturing, Corporate Development, Technical Development, Supply Chain, Quality, and Alliance Management. Prior to joining Spark, he worked at Sandoz, a Novartis Group company, where he rose through the ranks to become Chief Executive, Associate General Counsel, BD&L, Strategy, and Portfolio. Mr. Gerard also served at Aramark as an Assistant General Counsel. Also, he started his legal career at K&L Gates LLP, then moved on to Morrison & Foerster LLP before taking on his in-house counsel positions.
Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
On 18th August 2021, CABA reported 28-day results from the second dosage group at the 100 million cell dose level (mPV). The trial will assess early symptoms of potency through clinical studies. This includes a continual downturn in disease activity, a slight decrease or discontinuation of immunomodulatory therapies, etc.
Moreover, patients in the third cohort of the DesCAARTesTM study have begun receiving a treatment dosage of 500 million DSG3-CAART cells. In the fourth quarter of 2021, Cabaletta intends to release top-line results on biologic activity from the first two cohorts. Lastly, CABA will continue to publish new data for the DesCAARTesTM study as it becomes available, cohort by cohort.
